Resistance of cyclooxygenase-2 expressing pancreatic ductal adenocarcinoma cells against γδ T cell cytotoxicity

References

• Wang MT, Honn KV, Nie D. Cyclooxygenases, prostanoids, and tumor progression. Cancer Metastasis Rev 2007; 26:525-34; PMID:17763971; http://dx.doi.org/10.1007/s10555-007-9096-5
   PubMed Web of Science ®Google Scholar
• Harris SG, Padilla J, Koumas L, Ray D, Phipps RP. Prostaglandins as modulators of immunity. Trends Immunol 2002; 23:144-50; PMID:11864843; http://dx.doi.org/10.1016/S1471-4906(01)02154-8
   PubMed Web of Science ®Google Scholar
• Merati K, Said SM, Andea A, Sarkar F, Ben-Josef E, Mohammad R, Philip P, Shields AF, Vaitkevicius V, Grignon DJ, Adsay NV. Expression of inflammatory modulator COX-2 in pancreatic ductal adenocarcinoma and its relationship to pathologic and clinical parameters. Am J Clin Oncol 2001; 24:447-52; PMID:11586094; http://dx.doi.org/10.1097/00000421-200110000-00007
   PubMed Web of Science ®Google Scholar
• Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML, Sinicrope FA. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res 1999; 59:4356-62; PMID:10485483
   PubMed Web of Science ®Google Scholar
• Koshiba T, Hosotani R, Miyamoto Y, Wada M, Lee JU, Fujimoto K, Tsuji S, Nakajima S, Doi R, Imamura M. Immunohistochemical analysis of cyclooxygenase-2 expression in pancreatic tumors. Int J Pancreatol 1999; 26:69-76; PMID:10597402; http://dx.doi.org/10.1007/BF02781733
   PubMedGoogle Scholar
• Sreeramkumar V, Fresno M, Cuesta N. Prostaglandin E2 and T cells: friends or foes? Immunol Cell Biol 2012; 90:579-86; PMID:21946663; http://dx.doi.org/10.1038/icb.2011.75
   PubMed Web of Science ®Google Scholar
• Ahmadi M, Emery DC, Morgan DJ. Prevention of both direct and cross-priming of antitumor CD8+ T-cell responses following overproduction of prostaglandin E2 by tumor cells in vivo. Cancer Res 2008; 68:7520-9; PMID:18794140; http://dx.doi.org/10.1158/0008-5472.CAN-08-1060
   PubMed Web of Science ®Google Scholar
• Baratelli F, Lin Y, Zhu L, Yang SC, Heuze-Vourc'h N, Zeng G, Reckamp K, Dohadwala M, Sharma S, Dubinett SM. Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. J Immunol 2005; 175:1483-90; PMID:16034085; http://dx.doi.org/10.4049/jimmunol.175.3.1483
   PubMed Web of Science ®Google Scholar
• Martinet L, Fleury-Cappellesso S, Gadelorge M, Dietrich G, Bourin P, Fournie JJ, Poupot R. A regulatory cross-talk between Vg9Vd2 T lymphocytes and mesenchymal stem cells. Eur J Immunol 2009; 39:752-62; PMID:19197941; http://dx.doi.org/10.1002/eji.200838812
   PubMed Web of Science ®Google Scholar
• Kabashima-Niibe A, Higuchi H, Takaishi H, Masugi Y, Matsuzaki Y, Mabuchi Y, Funakoshi S, Adachi M, Hamamoto Y, Kawachi S, et al. Mesenchymal stem cells regulate epithelial-mesenchymal transition and tumor progression of pancreatic cancer cells. Cancer Sci 2013; 104:157-64; PMID:23121112; http://dx.doi.org/10.1111/cas.12059
   PubMed Web of Science ®Google Scholar
• Jimeno A, Amador ML, Kulesza P, Wang X, Rubio-Viqueira B, Zhang X, Chan A, Wheelhouse J, Kuramochi H, Tanaka K, et al. Assessment of celecoxib pharmacodynamics in pancreatic cancer. Mol Cancer Ther 2006; 5:3240-7; PMID:17172427; http://dx.doi.org/10.1158/1535-7163.MCT-06-0565
   PubMed Web of Science ®Google Scholar
• Vosooghi M, Amini M. The discovery and development of cyclooxygenase-2 inhibitors as potential anticancer therapies. Expert Opin Drug Discov 2014; 9:255-67; PMID:24483845; http://dx.doi.org/10.1517/17460441.2014.883377
   PubMed Web of Science ®Google Scholar
• Xu XF, Xie CG, Wang XP, Liu J, Yu YC, Hu HL, Guo CY. Selective inhibition of cyclooxygenase-2 suppresses the growth of pancreatic cancer cells in vitro and in vivo. Tohoku J Exp Med 2008; 215:149-57; PMID:18577844; http://dx.doi.org/10.1620/tjem.215.149
   PubMed Web of Science ®Google Scholar
• Dragovich T, Burris H, III, Loehrer P, Von Hoff DD, Chow S, Stratton S, Green S, Obregon Y, Alvarez I, Gordon M. Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial. Am J Clin Oncol 2008; 31:157-62; PMID:18391600; http://dx.doi.org/10.1097/COC.0b013e31815878c9
   PubMed Web of Science ®Google Scholar
• Lipton A, Campbell-Baird C, Witters L, Harvey H, Ali S. Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer. J Clin Gastroenterol 2010; 44:286-8; PMID:20216081; http://dx.doi.org/10.1097/MCG.0b013e3181cda097
   PubMed Web of Science ®Google Scholar
• Lunardi S, Muschel RJ, Brunner TB. The stromal compartments in pancreatic cancer: are there any therapeutic targets? Cancer Lett 2014; 343:147-55; PMID:24141189; http://dx.doi.org/10.1016/j.canlet.2013.09.039
   PubMed Web of Science ®Google Scholar
• Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64:9-29; PMID:24399786; http://dx.doi.org/10.3322/caac.21208
   PubMed Web of Science ®Google Scholar
• Oberg HH, Peipp M, Kellner C, Sebens S, Krause S, Petrick D, Adam-Klages S, Röcken C, Becker T, Vogel I, et al. Novel bispecific antibodies increase gd T-cell cytotoxicity against pancreatic cancer cells. Cancer Res 2014; 74:1349-60; PMID:24448235; http://dx.doi.org/10.1158/0008-5472.CAN-13-0675
   PubMed Web of Science ®Google Scholar
• Shojaei H, Oberg HH, Juricke M, Marischen L, Kunz M, Mundhenke C, Gieseler F, Kabelitz D, Wesch D. Toll-like receptors 3 and 7 agonists enhance tumor cell lysis by human gd T cells. Cancer Res 2009; 69:8710-7; PMID:19887600; http://dx.doi.org/10.1158/0008-5472.CAN-09-1602
   PubMed Web of Science ®Google Scholar
• Sipos B, Moser S, Kalthoff H, Torok V, Lohr M, Kloppel G. A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform. Virchows Arch 2003; 442:444-52; PMID:12692724
   PubMed Web of Science ®Google Scholar
• Murakami M, Naraba H, Tanioka T, Semmyo N, Nakatani Y, Kojima F, Ikeda T, Fueki M, Ueno A, Oh S, Kudo I. Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem 2000; 275:32783-92; PMID:10869354; http://dx.doi.org/10.1074/jbc.M003505200
   PubMed Web of Science ®Google Scholar
• Gupta NK, Dixit VK. Bioavailability enhancement of curcumin by complexation with phosphatidyl choline. J Pharm Sci 2011; 100:1987-95; PMID:21374628; http://dx.doi.org/10.1002/jps.22393
   PubMed Web of Science ®Google Scholar
• Pietschmann K, Beetz S, Welte S, Martens I, Gruen J, Oberg HH, Wesch D, Kabelitz D. Toll-like receptor expression and function in subsets of human gd T lymphocytes. Scand J Immunol 2009; 70:245-55; PMID:19703014; http://dx.doi.org/10.1111/j.1365-3083.2009.02290.x
   PubMed Web of Science ®Google Scholar
• Wesch D, Beetz S, Oberg HH, Marget M, Krengel K, Kabelitz D. Direct costimulatory effect of TLR3 ligand poly(I:C) on human gd T lymphocytes. J Immunol 2006; 176:1348-54; PMID:16424161; http://dx.doi.org/10.4049/jimmunol.176.3.1348
   PubMed Web of Science ®Google Scholar
• Helm O, Mennrich R, Petrick D, Goebel L, Freitag-Wolf S, Roder C, Kalthoff H, Röcken C, Sipos B, Kabelitz D, et al. Comparative characterization of stroma cells and ductal epithelium in chronic pancreatitis and pancreatic ductal adenocarcinoma. PLoS One 2014; 9:e94357; PMID:24797069; http://dx.doi.org/10.1371/journal.pone.0094357
   PubMed Web of Science ®Google Scholar
• Martinet L, Jean C, Dietrich G, Fournie JJ, Poupot R. PGE2 inhibits natural killer and gd T cell cytotoxicity triggered by NKR and TCR through a cAMP-mediated PKA type I-dependent signaling. Biochem Pharmacol 2010; 80:838-45; PMID:20470757; http://dx.doi.org/10.1016/j.bcp.2010.05.002
   PubMed Web of Science ®Google Scholar
• Chulada PC, Thompson MB, Mahler JF, Doyle CM, Gaul BW, Lee C, Tiano HF, Morham SG, Smithies O, Langenbach R. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 2000; 60:4705-8; PMID:10987272
   PubMed Web of Science ®Google Scholar
• Crofford LJ. COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol Suppl 1997; 49:15-9; PMID:9249646
   PubMedGoogle Scholar
• Hill R, Li Y, Tran LM, Dry S, Calvopina JH, Garcia A, Kim C, Wang Y, Donahue TR, Herschman HR, et al. Cell intrinsic role of COX-2 in pancreatic cancer development. Mol Cancer Ther 2012; 11:2127-37; PMID:22784710; http://dx.doi.org/10.1158/1535-7163.MCT-12-0342
   PubMed Web of Science ®Google Scholar
• Alfranca A, Iniguez MA, Fresno M, Redondo JM. Prostanoid signal transduction and gene expression in the endothelium: role in cardiovascular diseases. Cardiovasc Res 2006; 70:446-56; PMID:16458868; http://dx.doi.org/10.1016/j.cardiores.2005.12.020
   PubMed Web of Science ®Google Scholar
• Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999; 79:1193-226; PMID:10508233
   PubMed Web of Science ®Google Scholar
• Pino MS, Nawrocki ST, Cognetti F, Abruzzese JL, Xiong HQ, McConkey DJ. Prostaglandin E2 drives cyclooxygenase-2 expression via cyclic AMP response element activation in human pancreatic cancer cells. Cancer Biol Ther 2005; 4:1263-9; PMID:16319525; http://dx.doi.org/10.4161/cbt.4.11.2138
   PubMed Web of Science ®Google Scholar
• Ponti C, Gibellini D, Boin F, Melloni E, Manzoli FA, Cocco L, Zauli G, Vitale M. Role of CREB transcription factor in c-fos activation in natural killer cells. Eur J Immunol 2002; 32:3358-65; PMID:12432566; http://dx.doi.org/10.1002/1521-4141(200212)32:12%3c3358::AID-IMMU3358%3e3.0.CO;2-Q
   PubMed Web of Science ®Google Scholar
• Samten B, Howard ST, Weis SE, Wu S, Shams H, Townsend JC, Safi H, Barnes PF. Cyclic AMP response element-binding protein positively regulates production of IFN-g by T cells in response to a microbial pathogen. J Immunol 2005; 174:6357-63; PMID:15879136; http://dx.doi.org/10.4049/jimmunol.174.10.6357
   PubMed Web of Science ®Google Scholar
• Su Y, Jackson EK, Gorelik E. Receptor desensitization and blockade of the suppressive effects of prostaglandin E(2) and adenosine on the cytotoxic activity of human melanoma-infiltrating T lymphocytes. Cancer Immunol Immunother 2011; 60:111-22; PMID:20960188; http://dx.doi.org/10.1007/s00262-010-0924-z
   PubMed Web of Science ®Google Scholar
• Vang T, Abrahamsen H, Myklebust S, Horejsi V, Tasken K. Combined spatial and enzymatic regulation of Csk by cAMP and protein kinase a inhibits T cell receptor signaling. J Biol Chem 2003; 278:17597-600; PMID:12665526; http://dx.doi.org/10.1074/jbc.C300077200
   PubMed Web of Science ®Google Scholar
• Nishigaki N, Negishi M, Ichikawa A. Two Gs-coupled prostaglandin E receptor subtypes, EP2 and EP4, differ in desensitization and sensitivity to the metabolic inactivation of the agonist. Mol Pharmacol 1996; 50:1031-7; PMID:8863851
   PubMed Web of Science ®Google Scholar
• Patrignani P, Tacconelli S, Sciulli MG, Capone ML. New insights into COX-2 biology and inhibition. Brain Res Brain Res Rev 2005; 48:352-9; PMID:15850674; http://dx.doi.org/10.1016/j.brainresrev.2004.12.024
   PubMedGoogle Scholar
• Yamaguchi K, Nakano K, Nagai E, Chijiiwa K, Kinoshita M, Ohta M, Tanaka M. Ki-ras mutations in codon 12 and p53 mutations (biomarkers) and cytology in bile in patients with hepatobiliary-pancreatic carcinoma. Hepatogastroenterology 2005; 52:713-8; PMID:15966189
   PubMed Web of Science ®Google Scholar
• Kundu N, Ma X, Kochel T, Goloubeva O, Staats P, Thompson K, Martin S, Reader J, Take Y, Collin P, et al. Prostaglandin E receptor EP4 is a therapeutic target in breast cancer cells with stem-like properties. Breast Cancer Res Treat 2014; 143:19-31; PMID:24281828; http://dx.doi.org/10.1007/s10549-013-2779-4
   PubMed Web of Science ®Google Scholar
• Ma X, Holt D, Kundu N, Reader J, Goloubeva O, Take Y, Fulton AM. A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE-mediated immunosuppression and inhibits breast cancer metastasis. Oncoimmunology 2013; 2:e22647; PMID:23482441; http://dx.doi.org/10.4161/onci.22647
   PubMed Web of Science ®Google Scholar
• Chen Q, Muramoto K, Masaaki N, Ding Y, Yang H, Mackey M, Li W, Inoue Y, Ackermann K, Shirota H, et al. A novel antagonist of the prostaglandin E(2) EP(4) receptor inhibits Th1 differentiation and Th17 expansion and is orally active in arthritis models. Br J Pharmacol 2010; 160:292-310; PMID:20423341; http://dx.doi.org/10.1111/j.1476-5381.2010.00647.x
   PubMed Web of Science ®Google Scholar
• Sobolewski C, Cerella C, Dicato M, Ghibelli L, Diederich M. The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies. Int J Cell Biol 2010; 2010:215158; PMID:20339581; http://dx.doi.org/10.1155/2010/215158
   PubMedGoogle Scholar
• Lipton A, Harvey H, Witters L, Kerr S, Legore K, Campbell C. Gemcitabine/Irinotecan/celecoxib in pancreatic cancer. Oncology (Williston Park) 2004; 18:43-5; PMID:15685834
   PubMedGoogle Scholar
• Xu XF, Xie CG, Wang XP, Liu J, Yu YC, Hu HL, Guo CY. Selective inhibition of cyclooxygenase-2 suppresses the growth of pancreatic cancer cells in vitro and in vivo. Tohoku J Exp Med 2008; 215:149-57; PMID:18577844; http://dx.doi.org/10.1620/tjem.215.149
   PubMed Web of Science ®Google Scholar